NKTR-255 plus liso-cel shows promise in boosting CD8+ CAR T cells and improving remission in R/R LBCL.
New CAR T and bispecific therapies are reshaping myeloma care. Here's what the latest data reveals. Josie Ford, of Mass General Hospital, shared real-world efficacy and safety data on duvelisib and romidepsin in PTCL. Should interim PET scans still guide Hodgkin lymphoma treatment? Experts debate imaging, SUV changes, and biopsy use in HL. Experts discuss T-cell lymphoma care, new therapies, transplant timing, and the role of NGS in treatment decisions. The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.